KannaLife

KannaLife is a biopharmaceutical company that specializes in the research and development of cannabinoid therapeutics. The company is particularly known for its work in the field of neurodegenerative diseases, with a focus on hepatocellular carcinoma and chronic traumatic encephalopathy (CTE).

History[edit | edit source]

KannaLife was founded in 2010 with the aim of exploring the potential therapeutic uses of cannabinoids. The company was granted a license by the National Institutes of Health (NIH) to develop cannabinoid-based treatments for two types of brain damage: hepatic encephalopathy, which is caused by liver failure, and CTE, which is caused by repeated head trauma.

Research and Development[edit | edit source]

KannaLife's research is centered on the development of novel new drugs that can exploit the therapeutic potential of cannabinoids. The company's lead drug candidate, KLS-13019, is a cannabinoid-derived neuroprotective agent that is currently in preclinical development for the treatment of hepatic encephalopathy and CTE.

KannaLife's research has shown that KLS-13019 has the potential to reduce oxidative stress, inflammation, and cell death in the brain, all of which are implicated in the pathogenesis of hepatic encephalopathy and CTE. The company is currently conducting further preclinical studies to confirm these findings and to determine the optimal dosing regimen for KLS-13019.

Partnerships and Collaborations[edit | edit source]

KannaLife has established several strategic partnerships and collaborations to advance its research and development efforts. These include partnerships with academic institutions, such as the University of Pennsylvania and the Temple University School of Pharmacy, as well as collaborations with other biopharmaceutical companies.

Future Directions[edit | edit source]

KannaLife continues to explore the therapeutic potential of cannabinoids in the treatment of neurodegenerative diseases. The company's ongoing research and development efforts are focused on advancing KLS-13019 through preclinical development and into clinical trials.

References[edit | edit source]

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.